Carnegie Capital Asset Management LLC Has $4.60 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Carnegie Capital Asset Management LLC lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 73,537 shares of the company's stock after selling 15,180 shares during the period. Carnegie Capital Asset Management LLC owned 0.09% of CRISPR Therapeutics worth $4,603,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. CWM LLC boosted its stake in CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company's stock valued at $26,000 after purchasing an additional 260 shares during the period. Tradewinds Capital Management LLC boosted its stake in CRISPR Therapeutics by 545.5% during the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company's stock valued at $32,000 after purchasing an additional 600 shares during the period. Blue Trust Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter valued at about $32,000. Headlands Technologies LLC acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $34,000. Finally, BluePath Capital Management LLC acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $37,000. Institutional investors own 69.20% of the company's stock.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at approximately $11,711,062.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the firm's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at approximately $11,711,062.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Raju Prasad sold 3,524 shares of the firm's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the sale, the chief financial officer now owns 6,476 shares of the company's stock, valued at approximately $470,740.44. The disclosure for this sale can be found here. Insiders sold 134,410 shares of company stock worth $9,234,677 in the last quarter. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on CRSP. Needham & Company LLC reissued a "buy" rating and set a $90.00 target price on shares of CRISPR Therapeutics in a research note on Thursday. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a research note on Monday, February 26th. Wolfe Research began coverage on shares of CRISPR Therapeutics in a research note on Thursday, February 15th. They set a "peer perform" rating for the company. Wells Fargo & Company increased their target price on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an "equal weight" rating in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada increased their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a "sector perform" rating in a research note on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $74.93.

CRISPR Therapeutics Stock Down 3.2 %

CRISPR Therapeutics stock traded down $1.95 during mid-day trading on Monday, reaching $58.72. The company had a trading volume of 1,467,431 shares, compared to its average volume of 1,863,026. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The company has a 50 day moving average of $73.89 and a 200-day moving average of $63.30. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of -29.96 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. During the same quarter in the prior year, the company posted ($1.41) EPS. The company's quarterly revenue was up 3253.3% compared to the same quarter last year. On average, analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.